Bank of America began coverage on shares of Iambic Therapeutics (NASDAQ:IAM – Get Free Report) in a report issued on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $30.00 price target on the stock. Bank of America‘s target price would suggest a potential upside of 194.99% from the stock’s previous close.
Separately, Wall Street Zen raised Iambic Therapeutics to a “hold” rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $24.67.
Get Our Latest Research Report on Iambic Therapeutics
Iambic Therapeutics Stock Performance
Insiders Place Their Bets
In other Iambic Therapeutics news, Director Evan Lockwood Rachlin purchased 718,750 shares of the stock in a transaction on Friday, October 16th. The shares were purchased at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the acquisition, the director directly owned 2,588,248 shares of the company’s stock, valued at $41,411,968. This represents a 38.45% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Iambic Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Iambic Therapeutics
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
